Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results

Background: To evaluate survival and toxicities outcomes in a series of patients with intermediate-risk prostate cancer (PCa) treated with hypofractionated radiotherapy (HyRT) + androgen deprivation therapy (ADT) with or without image guided radiotherapy (IGRT) and to investigate the impact of different variables.Methods: This is a multi-centric study. From January 2005 and December 2019, we treated 313 intermediate risk Pca patients (T2b–T2c or Gleason Score 7 or pre-treatment PSA 10 to 20 ng/mL) with HyRT. Patients received 54,75 Gy in 15 fraction in 5 weeks plus 9 months of neo-adjuvant, concomitant and adjuvant ADT with or without IGRT.Results: Median follow-up was 91.6 months (range 5.1-167.8 months). Median OS was not reached, the 8 and 10-year OS were 81.9 % and 72.4%, respectively. Median CSS was not reached, the 8 and 10-year CSS were 97.9 % and 94.5%, respectively. PSA at first follow-up